Drug intelligence / Profile preview

Anthrax Adjuvant System

Development stage: Preclinical
Lead developer: Molecular Express
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Anthrax Adjuvant System is a preclinical-stage vaccine adjuvant candidate developed by Molecular Express. It utilizes the company's proprietary VesiVax/IAM (Immunomodulator Adsorption to Membranes) platform to enhance immune responses to anthrax antigens. The system is designed to improve the efficacy of anthrax vaccines by presenting antigens in a liposomal nanoparticle format with associated immunomodulators, thereby stimulating a more robust and protective immune response against *Bacillus anthracis*. This approach aims to provide rapid and long-lasting protection, potentially improving the dosing schedule and overall effectiveness of anthrax immunization strategies.

Targets

TLR9 (Toll-like receptor 9)

Beyond the preview

Go deeper on Anthrax Adjuvant System.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anthrax Adjuvant System.

Explore the full profile